drugset / Trial / NCT00692172

Open-label Study to Evaluate Safety of Multiple Courses of IM Alefacept During Treatment of Chronic Plaque Psoriasis

NCT00692172

Phase 3 Completed 175 enrolled Astellas Pharma Inc Biogen · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

An extension study to evaluate safety and tolerability of up to 3 additional courses of IM alefacept in patients with chronic plaque psoriasis who have been previously treated with 1 or 2 courses of IM alefacept.

Timeline

Start
2001-12
Primary completion
2004-11
Completion
2004-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Alefacept Protein / enzyme biologic Intramuscular

Indications